Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Mar 5;29(5):2011–2018. doi: 10.3892/or.2013.2329

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013, Spandidos Publications

This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

PMC Copyright notice

MK8033 acts synergistically with carboplatin plus paclitaxel (CarboTaxol or C/T) to inhibit OVCA cell line proliferation. (A) Line graphs show percent OVCA cell viability after 72-h incubation with MK8033, carboplatin plus paclitaxel (carboplatin-to-paclitaxel molar ratio of 20,000:1), and MK8033 plus carboplatin-paclitaxel at constant ratios of 1–2.5:1. Bottom and top horizontal axes indicate MK8033 and carboplatin (in carboplatin-paclitaxel mixture) concentrations, respectively. (B) IC₅₀ values of carboplatin-paclitaxel, MK8033 plus carboplatin-paclitaxel, and MK8033 as well as combination index values of synergistic activity in OVCA cell lines. Count (n) refers to the number of replicate experiments.